Leading Beyond The Lab

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed?This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Bioptimus, with decades of experience spanning artificial intelligence, computational biology, academia and big tech, including leadership roles at Google, and work influenced by breakthroughs such as DeepMind’s AlphaFold.In this episode, Jean-Philippe covers:• Why Bioptimus is focused on understanding patient biology, not simply designing molecules, and why that could change drug development.• How AI-powered decision systems could improve translational research, clinical trial design, patient recruitment and disease prediction.• Why Jean-Philippe left Google to build Bioptimus, and why foundation models for biology may represent a major shift in medicine.• How partnerships across healthcare systems, pharma and research institutions are helping build the data infrastructure behind biological foundation models, with perspectives shaped alongside leaders including Sarah Teichmann (Professor at Cambridge University) and Caroline Uhler (Professor at MIT)• What makes AI in biology defensible, from proprietary data partnerships and elite interdisciplinary teams, to support from investors including Edward Kliphuis (Sofinnova Partners), Bpifrance, Cathay Investments.A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading.Be sure to check out the full episode.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talentTikTok: https://www.tiktok.com/@artotalentApple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentJean-Philippe VertCEO at BioptimusLinkedIn: https://www.linkedin.com/in/jean-philippe-vert/Lawrence RoseTalent Solutions Director at ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps00:00 Introduction and vision for AI as a universal simulator of biology01:41 Introducing Jean-Philippe Vert and @Bioptimus02:27 What Bioptimus is doing differently in AI biology07:46 AI decision systems and improving clinical development12:52 Early disease detection and predictive healthcare15:28 Why Jean-Philippe left @Google19:21 Building and sourcing biological data at scale22:19 Partnerships and foundation models28:04 Lessons from big tech33:23 Defensibility in AI biology37:09 Building interdisciplinary teams and culture39:28 AI in healthcare, hype versus infrastructure41:20 What AI means for doctors43:10 What may define lasting AI-biology companies45:05 Challenges of building Bioptimus48:13 Prioritisation and deciding where to focus51:33 Mentorship, leadership and building teams53:02 Communicating vision to boards and investors55:33 What success looks like in ten years#LeadingBeyondTheLab #ARTOTalent #TechBio #ArtificialIntelligence #DrugDiscovery #ComputationalBiology #PrecisionMedicine Hosted on Acast. See acast.com/privacy for more information.

AI is beginning to uncover medicines that humans alone could never design.This week on another episode of Leading Beyond the Lab, we host James Field, CEO and Founder of LabGenius Therapeutics, a company pioneering the use of machine learning, robotics, and synthetic biology to engineer the next generation of therapeutic antibodies.With over a decade of experience spanning AI-driven drug discovery, protein engineering, and synthetic biology, James founded LabGenius Therapeutics to rethink how biologic medicines are discovered. In this episode, James discusses:- The founding story of LabGenius Therapeutics and how its AI-guided experimentation platform is transforming antibody engineering.- The companies backing by leading investors including Kindred Capital (Leila Zegna), Lux Capital, Obvious Ventures, M Ventures, and Octopus Ventures, and is guided by industry leaders such as Edwin Moses, the company’s Chairman and a veteran biotech executive.- LabGenius Therapeutics' collaboration with Sanofi, and how partnerships between biotech startups and global pharma companies are helping translate AI-designed antibodies into real therapeutic pipelines.- The importance of global scientific conferences such as European Society for Medical Oncology, where breakthroughs in oncology and biologics are shaping the future of therapeutic development.- The mentors and inspirations that shaped his journey into biotech, from his university lecturers at Imperial College London to industry leaders like Edwin Moses, who now serves as Chairman of LabGenius Therapeutics and has played a key role in guiding the company’s growth.If you're interested in AI-driven drug discovery, biotech entrepreneurship, and the future of medicine, this episode is one you won’t want to miss.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Website: https://arto-talent.com/Youtube: https://www.youtube.com/@artotalentDr. James FieldLinkedIn: https://www.linkedin.com/in/james-field-7518a05b/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:02:40 Rewriting the Rules of Drug Discovery16:21 Scaling Innovation37:29 AI, Motivation & Purpose Hosted on Acast. See acast.com/privacy for more information.

What if a single injection could teach the immune system to eliminate cancer, and keep it away?This week, in another episode of Leading Beyond the Lab, Lawrence Rose sits down with Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, one of the most quietly compelling stories in cancer immunotherapy today.With over 30 years of experience spanning academic medicine, clinical immunology, rheumatology, oncology, and global pharmaceutical leadership, Paul Peter brings a rare clinician-scientist perspective to biotech leadership. Prior to Candel, he served as Chief Immunology Officer and Global Head of Development at GSK (led by Luke Miels) , where he helped shape immunology and oncology strategy at scale. Paul Peter is also founder and previous chair of the dept of clinical immunology and rheumatology at Amsterdam UMC.In this episode, Paul Peter covers:- The mission behind Candel Therapeutics and why viral immunotherapy represents a fundamentally new modality, shifting the goal from helping patients live longer with cancer to helping them live without cancer.- Why Candel’s lead programs (including CAN-2409) are gaining serious scientific credibility, supported by leaders such as Nobel laureate James P. Allison and the "father of CAR-T cell therapy" Carl June, and how this external validation is changing industry and investor perception.- Lessons from past paradigm shifts in medicine, drawing on his early academic work at Leiden University, where once-dismissed antibody therapies later became standard of care, a parallel to today’s scepticism around viral immunotherapy.- How leadership, culture, and decision-making drive biotech success, shaped by his experience building teams in academia, transforming R&D at GSK, and learning large-scale leadership from mentors like Lord Patrick Vallance.- Why flexible operating models matter in biotech, including Candel’s approach to commercialisation through partners such as IDEA Pharma (led by Mike Rea) and Globe Life Sciences (Jonathon Mitchell), and cautionary lessons from companies like Oncorus and Replimune.Be sure to check out this episode to hear how Paul-Peter Tak is helping redefine what’s possible in cancer immunotherapy - and what it takes to lead beyond the lab.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ngInstagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qrTikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575Youtube: https://www.youtube.com/@life_sciencesWebsite: https://arto-talent.comPaul Peter TakCEO at Candel TherapeuticsLinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:01:50 Candel's Mission19:51 The US Promising Future for Candel35:44 Culture at Candel40:44 Paul Peter's Motivations as CEO Hosted on Acast. See acast.com/privacy for more information.

From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options?This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development.A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry.In this episode, Amit covers:• How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09)• What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29)• The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58)• Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37)• Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00)If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time.Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders.Follow ARTO: https://linktr.ee/arto_talentAmit RakhitLinkedIn: https://www.linkedin.com/in/amit-rakhit/Lawrence RoseLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Introduction and background01:09 Cell therapy and BlueRock Therapeutics’ mission03:29 Leadership, credibility, and execution04:58 CEO vs CMO roles in biotech06:37 Authenticity, inclusion, and culture09:24 What separates successful biotechs12:00 Physician scientists transitioning into industry18:34 Career-defining moments and resilience22:38 The future of cell therapy and emerging modalities24:32 AI in drug discovery and clinical development26:26 Closing thoughts and where to connect#LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment Hosted on Acast. See acast.com/privacy for more information.

This episode is a masterclass in how world-class life sciences investors think about risk, conviction, and real patient impact.This week on Leading Beyond The Lab, Lawrence Rose sat down with Nikhil Thatte, Partner at Lumira Ventures, a leading Canadian life sciences venture capital firm, with over a decade of experience backing transformative biotech and medtech companies across North America.In this conversation, Nikhil shares how Lumira Ventures has built a top-quartile VC track record over multiple market cycles, investing across therapeutic areas including oncology, gene editing, gene therapy, immunology, cardiometabolic disease, and medical devices. He also reflects on his journey helping scale globally impactful healthcare companies while staying grounded in patient outcomes.In this episode, Nikhil covers:• How Lumira Ventures evaluates investment opportunities in today’s biotech market, including why clinical data, valuation discipline, and a clear path to liquidity now matter more than ever (08:38)• Lessons from Lumira’s major exit successes, including Histosonics and Endotronix, and what made these companies stand out from an investor perspective, with insights into leadership, timing, and execution alongside Mike Blue at Histosonics (02:33)• What truly differentiates exceptional founders and management teams, with real examples of conviction moments backing leaders such as Joanna Stanicka at Axonis and Jade Doucet-Martineau at Puzzle Med (22:08)• Why Canada punches above its weight in life sciences innovation, the structural challenges holding the ecosystem back, and what must change to retain value domestically, including reflections on Canadian success stories discussed throughout the episode (17:40)• The vision behind the Cancer Breakthrough Fund, Lumira’s partnership with the Terry Fox Foundation, and how this model brings new capital, clinical expertise, and impact-driven investors into oncology innovation (31:08)If you want a rare, honest look inside how top life sciences VCs assess opportunity, leadership, and long-term value creation, this is an episode you don’t want to miss.Follow ARTO: https://linktr.ee/arto_talentNikhil ThatteLinkedIn: https://www.linkedin.com/in/nikhil-thatte-72372333/Lawrence RoseDirector at ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Introduction to Nikhil Thatte and Lumira Ventures02:33 Major exits including Histosonics and Endotronix05:30 Fund V and what drives LP conviction today08:38 How Lumira evaluates deals in the current biotech market17:40 Canada’s competitive advantages and ecosystem challenges22:08 Backing exceptional founders and leadership teams31:08 The Cancer Breakthrough Fund and Terry Fox Foundation partnership37:00 Technologies and trends shaping the next 5–10 years41:16 Patient impact and what ultimately motivates long-term investing#LeadingBeyondTheLab #ARTOTalent #LifeSciences #BiotechVC #Medtech #VentureCapital #CanadianInnovation Hosted on Acast. See acast.com/privacy for more information.

25 years of life sciences venture experience in one episode.This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His track record includes multiple successful exits, advising boards, working across Medtech, Biotech, digital health and Techbio, and supporting companies through regulatory approval, clinical development and commercial scale.In this episode, Joey covers:Joey dives into his career spanning 25 years of Life Sciences experience, from early biotech to leading global investment firms.He unpacks the frameworks and philosophies that guide his investment decisions across the Life Sciences ecosystem.Joey reflects on a standout investment, what made it succeed, and the lessons it offers future founders.A candid discussion on what strong leadership looks like in high-growth Life Sciences ventures.Joey shares exactly what he looks for in a pitch, and what turns him off instantly.Looking ahead, Joey reveals where he’s placing bets and what excites him most about the next wave of Life Sciences innovation.Check out this episode if you want a grounded, practical understanding of how life sciences companies are assessed, funded and supported behind the scenes, and how founders can communicate, hire and plan more effectively on the path to scale.Follow ARTO!LinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentLawrence RoseCo-Founder + Talent Solutions Director at @ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Joey MasonVenture Advisor @SofinnovaVenture Partner @Claret Capital PartnersLinkedIn: https://www.linkedin.com/in/joey-mason/Timestamps01:09 Joey’s Career05:14 Investment approaches19:17 Most successful investment28:20 Leadership32:46 How to pitch to Joey Mason42:21 Future plans#LeadingBeyondTheLab #ARTOTalent #LifeSciences #VentureCapital #VentureDebt #Medtech #Biotech #TechBio #DigitalHealth #IrelandEcosystem #Pharma #InvestmentStrategy Hosted on Acast. See acast.com/privacy for more information.

A once-in-a-century transformation, and the leader driving it.This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history.With over 25+ years of global biopharma leadership experience, spanning pivotal roles at Amgen, Sanofi, and Orphazyme, Christophe brings a rare combination of commercial excellence, turnaround leadership, and global market insight. He also shares how senior leaders such as Murdo Gordon helped shape his approach to building high-performing, people-centric teams.In this episode, Host of Leading Beyond The Lab, @Lawrence Rose, discusses with Christophe how he’s reshaping a century-old European company into a modern, innovation-driven global leader, covering:Transforming LEO Pharma, from financial urgency to sustainable growth, cultural renewal, and long-term clarity.The Partner and Development model, and why global players like Gilead Sciences and Boehringer Ingelheim have chosen LEO as a trusted innovation partner.Leadership and culture at scale, transparency, conviction, rebuilding confidence, and empowering bold talent.Preparing for a future IPO, aligning profitability, growth, and a clear 5-year vision for employees, shareholders, and partners.Europe vs. the US in the next decade of biotech, why the US has become LEO’s largest affiliate and what this shift means for global competitiveness.This episode is a rare look at what it truly takes to modernise a legacy company while keeping innovation, collaboration, and leadership at the core.Be sure to check out this episode - one of our most important conversations to date.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentChristophe BourdonCEO of LEO PharmaLinkedIn: https://www.linkedin.com/in/christophe-bourdon-77a62b6/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 LEO’S Recent Achievements06:58 Shaping a Modern LEO Pharma16:30 LEO Pharma’s IPO Journey25:39 Christophe’s Leadership Hosted on Acast. See acast.com/privacy for more information.

If you're not paying attention to nuclear medicine, Danielle Meyrick will change that in under five minutes.This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as both a scientific pioneer and commercial strategist. Her career has spanned from launching radiopharmaceutical therapies in hospitals to shaping global strategies for biotech companies. If you're serious about understanding the future of oncology, this is the episode to watch. In this episode we cover:Why nuclear medicine is having a moment - and what makes radiotheranostics the most promising modality in oncology today.From PhD to MD – Danielle’s unconventional path to medicine, and how her dual perspective shaped her leadership style.What it takes to commercialise complex therapies – lessons from inside large pharma, mid-stage biotechs, and early-stage ventures.The clinical data that changed everything – and how early adopters leveraged compassionate use to gain momentum.What’s next for EPIC Theranostics – and why workforce readiness and isotope supply could make or break the sector.If you're in biotech, pharma, or medtech, this episode is a masterclass in strategic thinking and scientific depth. Watch now and get ahead of where oncology is going.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDanielle MeyrickCo-Founder + Director At EPIC Theranostiocs LinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings06:12 Nuclear Medicine09:26 Characteristics of a Good Drug Developer14:13 Future of Radiotheranostics20:05 Approaching Challenges26:52 Advice29:25 Motivations30:56 Greatest Achievements#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of experience across translational science, drug development and leadership in global R&D. His conviction, clarity, and track record - including developing molecules that have become partnered, acquired and approved - makes this conversation a must-listen for anyone in life sciences leadership.In this episode, we cover:How Maxion is building a new therapeutic modality using KnotBody technology to tackle autoimmune and inflammatory diseasesWhy conviction, speed, and storytelling are non-negotiable in translational drug developmentLessons from Genentech, MorphoSys, and Kymab on building pipelines, teams, and partnershipsWhat investors really look for - and how Maxion secured a competitive Series A in a tough marketHow to hire and scale for scientific excellence without losing agility or collaborationTune in for a dynamic, insightful conversation with one of biotech’s most experienced and thoughtful leaders.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentArndt SchotteliusCEO at Maxion TherapruticsLinkedIn: https://www.linkedin.com/in/arndt-schottelius-md-ph/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings06:46 Translational Science08:55 Lessons in Biotech Leadership25:23 Maxion - Culture and Roundup#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for.We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene.In this episode, Bhaskar dives deep into:· How Triveni is building a first-in-class pipeline targeting the kallikrein system - a bold bet to treat severe skin and inflammatory conditions by tackling novel biology.· What it means to be a founder’s CMO, and how great science needs the right development strategy to make a difference.· Candid stories from his past roles at Nimbus (which sold its TYK2 program to Takeda for $4B) and Janssen, where he helped guide first-in-class therapies from Phase 1 to pivotal trials.· Why bispecifics may be risky but worth it, and how Triveni is using novel biologics to crack tough diseases like atopic dermatitis.· Advice for executives: how to balance ambition and discipline, when to say no, and why choosing the right team members matters as much as the science.🎙 Bhaskar doesn’t just talk science - he connects molecular biology to patient need, clinical strategy, and company vision with clarity and purpose.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentBhaskar Srivastava CMO at Triveni BioLinkedIn: https://www.linkedin.com/in/bhaskar-srivastava-355a9ab1/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings15:44 Success & Growth in Biotech28:43 Investing in Biotech34:23 The Future of Dermatology & Triveni Bio#LeadingBeyondTheLab #ARTOTalent #Biotechnology  Hosted on Acast. See acast.com/privacy for more information.

To anyone interested in life science VC investment – you need to watch this.In this episode, we’re joined by Dr. Sascha Berger, a biotech investment director based in Saudi Arabia and a very experienced life science investor globally. With nearly two decades in the industry, he’s seen breakthroughs, pivots, and billion-dollar transactions.He reveals:Saudi Arabia’s high-stakes plan to become a global biotech superpower by 2040 - and why it could disrupt the industry as we know it.The real role of a VC beyond the money - how top investors become game-changing partners for founders.Raw stories from the front lines - startups on the brink of collapse that fought back to success.No-fluff advice for first-time founders on building the right team and surviving the brutal biotech rollercoaster.A global insider’s view on the next wave of innovation - from Boston’s biotech streets to the Middle East’s rising hubs.This is one of our most unfiltered and insightful episodes yet - a must-watch for founders, investors, or anyone who wants to see where life sciences is really heading.🎧 Tune in now to hear how a leading investor is driving biotech’s next era.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentSascha BergerSaudi Arabia Biotech InvestorLinkedIn: https://www.linkedin.com/in/sasber/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings08:04 Investing in Success26:13 Saudi Arabia - The Future36:29 How to Secure Investment#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Nicholas Reder, who’s pushing the boundaries in AI-driven spatial tissue analysis, with a mix of experience and insights:Nick is the Founder & CEO at Alpenglow Biosciences, pioneers in AI-powered 3D spatial biology that transforms how we see and understand tissue biopsies.10+ years in translational research, with degrees in biochem, epidemiology, and medicine – plus a residency and fellowship in pathology at the University of Washington.Co-developed a groundbreaking open-top light-sheet microscope – now the core of Alpenglow’s tech.Nick is a major conference speaker at AACR, SID, PMWC, NextGen Omics, BIO International and more, and has won the Castleman Award - the highest global honour for pathologists under 40.In this episode, we discuss a range of topics including Alpenglow’s current success and what the future looks like, hiring talent within techbios, as well and leadership challenges within the computational biology space. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentNicholas RederFounder + CEO at Alpenglow BiosciencesLinkedIn: https://www.linkedin.com/in/nicholas-reder-210a578b/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings & Alpenglow04:54 AI & Hiring Talent14:58 Challenges / Key Triggers When Hiring19:36 Alpenglow Biosciences24:14 What’s Next - Quickfire Round#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.

In this episode, we sit down with Dr. Frank Watanabe, a titan of biotech and pharma, and leader shaping the future of medicine:CEO of Arcutis Biotherapeutics, one of the few commercial stage Dermatology focused Biopharma companies; leading them from startup to IPO to commercial success.25+ years in biotech and pharma with expertise across of various Therapeutic areas.Proven leader in life sciences, known for building and scaling companies from early-stage to FDA approval - with leadership forged from time spent in the U.S. Navy.Former roles at Kythera, Lilly Amgen, and Allergan - driving strategy, R&D, and game-changing product launches.Champion of innovation, access, and purpose-driven leadership across the biopharma ecosystemIn this episode, we discuss everything from How Frank built Arcutis, motivation and Self-Improvement that is grounded from his experience in the Navy, revealing the key to success as a leader in the industry. This conversation applies broadly to all types of connections in the Life Sciences Industry, and aims to educate and inspire those who want to excel in leadership.Follow ARTOLinkedIn: https://www.linkedin.com/company/artotalentSpotify: Leading Beyond The LabInstagram: Instagram (@arto.talent)TikTok: artotalent on TikTokApple Podcasts: Leading Beyond The LabWebsite: HomeYoutube: ARTO RecruitmentDr. Frank WatanabePresident, CEO At ArcutisLinkedIn: https://www.linkedin.com/in/frank-watanabe-419711/Lawrence RoseCo-Founder + Talent Solutions Director At ARTOLinkedIn: https://www.linkedin.com/in/lawrencerose/Timestamps:00:00 Career Beginnings + Arcutis05:01 Leadership & Growth20:52 Motivation & Self Improvement27:40 Personality Traits To Succeed In Pharma33:30 What’s Next For Arcutis#LeadingBeyondTheLab #ARTOTalent #Biotechnology #Dermatology Hosted on Acast. See acast.com/privacy for more information.